A Phase 3 interventional study of Dexamethasone sodium phosphate in Ataxia Telangiectasia, sponsored by Quince Therapeutics S.p.A.. Terminated at 21 sites in 9 countries. Open to participants aged 6 Years and older. Per ClinicalTrials.gov, last updated 2026-05-05.
Sponsored by Quince Therapeutics S.p.A. · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 16 studies in Ataxia Telangiectasia with a site in United States — 2 open to participants now, 4 under way, 1 of them phase 3. Ataxia Telangiectasia · United States.
Among the 16 studies in Ataxia Telangiectasia with a site in United States, this one is the 3rd largest by enrollment of the 13 interventional ones that give a count, is one of 2 that started in 2024, is one of 4 in phase 3, and was the 14th registered.
42 studies on the registry are indexed under Ataxia Telangiectasia; 7 are open to participants now.
Browse Ataxia Telangiectasia studies →2 of the 16 studies in Ataxia Telangiectasia with a site in United States are open now. Recruiting first, the newest first:
Timothy Yu · Sites in United States
Ages 0–17
Sanford Health · Sites in United States
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 5 Ataxia Telangiectasia studies recruiting now, 3 set no upper age limit and 2 stop at 75 or younger; 3 take children under 18; 1 takes healthy volunteers.
This study: 6 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
16 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 4 · Phase 3 4
First in 2002; this study’s year is marked. 2 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 101 is above the median of 30 across 28 interventional studies indexed under Ataxia Telangiectasia.
Median enrollment 20 across the 13 interventional studies, 317 across the 3 observational. Of the 10 that completed or were terminated, 5 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
9 of 16 have an industry lead sponsor. The 10 most frequent:
Quince Therapeutics S.p.A. is the lead sponsor of 10 studies on the registry; none are open to participants now.
Quince Therapeutics S.p.A. has 4 studies filed under Ataxia Telangiectasia — fewer than ten, so there is no comparison to draw.
1 of the studies in Ataxia Telangiectasia with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05692596H. Lee Moffitt Cancer Center and Research InstituteThe Pancreas Interception Center (PIC) for Early Detection, Prevention, and Novel Therapeutics | 2027-07 |
Add it to your calendar (.ics) → With an account.
Among the 16 studies in Ataxia Telangiectasia with a site in United States, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is an international, multi-center, prospective, open-label, non-comparative study aiming to provide access to treatment with EryDex to ataxia telangiectasia (A-T) patients who completed the IEDAT-04-2022 trial which studied the neurological effects of EryDex on subjects with ataxia telangiectasia (NEAT trial).
The IEDAT-05-2024 study aims to provide EryDex (dexamethasone sodium phosphate encapsulated into autologous erythrocytes) treatment to all participants in the IEDAT-04-2022 (NEAT) study, who complete the study assessments, do not -have safety contraindications to continuation of treatment, and who provide informed consent. The open-label extension (OLE) treatment period will be 12 months. Participants will be considered to have completed the study when Visit 14 (Safety Follow-up) has been performed.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
intravenous (IV) infusion of dexamethasone sodium phosphate (DSP) encapsulated in autologous erythrocytes using the EryDex System (EDS)
Drug: Dexamethasone sodium phosphate
Dexamethasone Sodium Phosphate encapsulated in autologous erythrocytes and administered via intravenous (IV) infusion
Number of Participants With Treatment Emergent Adverse Events
Number of participants presenting at least one treatment emergent adverse event (TEAE)
Time frame: through study completion, up to approximately 13 months
Number of Participants With Treatment Emergent Adverse Events Leading to Intervention Discontinuation
Number of participants presenting at least one treatment emergent adverse event (TEAE) leading to intervention discontinuation
Time frame: through study completion, up to approximately 13 months
Number of Participants With Serious Adverse Events
Number of participants presenting at least one serious adverse event (SAE)
Time frame: through study completion, up to approximately 13 months
102 participants completed the full treatment period in the IEDAT-04-2022 study (NEAT), 101 NEAT study participants subsequently consented and enrolled in the open-label extension study IEDAT-05-2024 study (NEAT-OLE).
| Milestone | Dexamethasone Sodium Phosphate |
|---|---|
| Started | 101 |
| Completed | 0 |
| Not completed | 101 |
| Withdrew: Study terminated by sponsor. no completers | 101 |
Number of participants presenting at least one treatment emergent adverse event (TEAE)
| Participants | Dexamethasone Sodium Phosphate |
|---|---|
| Number of Participants With Treatment Emergent Adverse Events | 71 |
Number of participants presenting at least one treatment emergent adverse event (TEAE) leading to intervention discontinuation
| Participants | Dexamethasone Sodium Phosphate |
|---|---|
| Number of Participants With Treatment Emergent Adverse Events Leading to Intervention Discontinuation | 1 |
Number of participants presenting at least one serious adverse event (SAE)
| Participants | Dexamethasone Sodium Phosphate |
|---|---|
| Number of Participants With Serious Adverse Events | 5 |
Collected over From first dose through study completion approximately 13 months. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Dexamethasone Sodium Phosphate | 0/101 (0%) | 5/101 (5%) | 71/101 (70.3%) |
| Event | Dexamethasone Sodium Phosphate |
|---|---|
| ConstipationGastrointestinal disorders | 1/101 |
| TachycardiaCardiac disorders | 1/101 |
| Gastrostomy tube site complicationInjury, poisoning and procedural complications | 1/101 |
| Influenza AInfections and infestations | 1/101 |
| BronchospasmRespiratory, thoracic and mediastinal disorders | 1/101 |
| Lymphadenopathy in nasopharynxGeneral disorders | 1/101 |
| Event | Dexamethasone Sodium Phosphate |
|---|---|
| PruritusSkin and subcutaneous tissue disorders | 18/101 |
| VomitingGastrointestinal disorders | 12/101 |
| NasopharyngitisInfections and infestations | 11/101 |
| Upper respiratory tract infectionInfections and infestations | 9/101 |
| Viral infectionInfections and infestations | 7/101 |
| PyrexiaGeneral disorders | 7/101 |
| DiarrhoeaGastrointestinal disorders | 6/101 |
| GastroenteritisGastrointestinal disorders | 6/101 |
| InfluenzaInfections and infestations | 6/101 |
| CoughRespiratory, thoracic and mediastinal disorders | 6/101 |
The total set (N=101) included all patients who provided informed consent or assent as documented by a date of informed consent or date of assent.
| Age, Categorical(Participants) | Dexamethasone Sodium Phosphate |
|---|---|
| <=18 years | 101 |
| Between 18 and 65 years | 0 |
| >=65 years | 0 |
| Sex: Female, Male(Participants) | Dexamethasone Sodium Phosphate |
|---|---|
| Female | 48 |
| Male | 53 |
| Race (NIH/OMB)(Participants) | Dexamethasone Sodium Phosphate |
|---|---|
| American Indian or Alaska Native | 0 |
| Asian | 6 |
| Native Hawaiian or Other Pacific Islander | 0 |
| Black or African American | 5 |
| White | 86 |
| More than one race | 0 |
| Unknown or Not Reported | 4 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Dec 2024 to primary completion in Jan 2026, 13 months.
Results were first posted in May 2026, 3 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Dexamethasone phosphate
Quince Therapeutics S.p.A.